HANDS Act
- Sponsor
- Rep. Pettersen, Brittany [D-CO-7]
- Committees
- Ways and Means Committee (primary)
- Last action
- Sep 3, 2025
Bottom line
The HANDS Act expands access to life-saving opioid overdose reversal drugs by eliminating cost-sharing and mandating coverage across major federal health programs for at-risk individuals upon discharge from certain healthcare settings.
What it actually does
This bill mandates no-cost coverage for preventive opioid overdose reversal drugs, such as naloxone, under Medicare, Medicaid, and TRICARE. It requires these drugs to be furnished by clinical personnel to individuals determined to be at risk for an opioid overdose when they are discharged from a hospital, emergency department, or ambulatory surgical center, along with administration instructions. The bill also directs federal agencies to issue guidance for state boards and hospitals to facilitate distribution and billing.
Proponents argue
Supporters argue that this bill directly addresses the ongoing opioid crisis by making naloxone more accessible to those most at risk, leveraging critical healthcare touchpoints like hospital discharge to prevent overdose deaths. They emphasize that removing financial barriers for a life-saving preventive measure is a crucial step in public health.
Opponents contend
Potential opponents might raise concerns about the fiscal implications for federal and state budgets due to expanded coverage, the administrative burden on healthcare providers for screening and distribution, or argue that while important, this measure does not address the underlying causes of opioid addiction.
The bill is concise and clearly structured, allowing an informed reader to understand its core provisions and implications relatively quickly.
Section 2(a)(1)-(2)
No-Cost Medicare Coverage for Preventive Opioid Overdose Reversal Drugs
This provision amends the Social Security Act to include 'preventive opioid overdose reversal drugs' as a covered medical service under Medicare Part B, effective January 1, 2026. It defines these drugs as intranasal or intramuscular naloxone furnished by qualified clinical personnel to inpatients or emergency department/ambulatory surgical center patients who are determined to be at risk for an opioid overdose, specifically at the time of their discharge, along with instructions for use.
Supporters argue
Proponents argue that this provision strategically intervenes at a high-risk moment (hospital discharge) to prevent overdoses among a vulnerable population, directly addressing a gap in care for Medicare beneficiaries.
Critics contend
Opponents may express concerns about the administrative burden on healthcare providers to screen patients and manage the distribution process, or the potential for increased costs to the Medicare program.
Tradeoffs
The provision balances the public health benefit of widespread naloxone access with the administrative and financial implications for healthcare providers and the Medicare system.
Section 2(a)(3)-(4)
Elimination of Medicare Deductibles and Coinsurance for Naloxone
This section amends the Social Security Act to prohibit deductibles, coinsurance, and other cost-sharing for preventive opioid overdose reversal drugs under both Medicare Part B and Medicare Advantage plans. This means that eligible Medicare beneficiaries will receive these drugs at no out-of-pocket cost, effective January 1, 2026.
Section 2(b)
Mandatory Medicaid Coverage and No Cost-Sharing for Naloxone
This comprehensive section amends multiple parts of the Social Security Act related to Medicaid. It mandates that state Medicaid programs and alternative benefit plans must cover preventive opioid overdose reversal drugs, effective January 1, 2026. Furthermore, it prohibits states from imposing any deductibles, cost-sharing, or similar charges for these drugs and ensures that federal rebate requirements apply to them.
Section 2(c)
No-Cost TRICARE Coverage for Preventive Opioid Overdose Reversal Drugs
This provision amends Title 10 of the United States Code to ensure that eligible beneficiaries under TRICARE, the healthcare program for military service members, veterans, and their families, are not required to pay any cost-sharing amount for preventive opioid overdose reversal drugs. This coverage becomes effective on January 1, 2026, aligning TRICARE with the other federal health programs in the bill.
Section 2(d)
Regulatory Guidance for State Boards and Hospitals
This section mandates two sets of guidance to be issued within one year of the Act's enactment. The Commissioner of Food and Drugs must issue guidance for state boards of pharmacy, nursing, and medicine to enhance safe and effective hospital-based dispensing and distribution of opioid overdose reversal drugs and eliminate barriers. Concurrently, the Secretary of Health and Human Services must issue guidance for hospitals regarding the proper billing procedures for these preventive drugs.
This subsection clarifies that nothing in the Act should be construed to require a provider of services or supplier to furnish a preventive opioid overdose reversal drug to an individual at risk of an opioid overdose.
Section 2(e)
Why it matters:This type of provision is typically included to clarify the scope of the legislation and prevent unintended mandates, preserving provider autonomy and avoiding potential legal challenges related to forced distribution. It's standard legislative practice to define what a bill *doesn't* do.
Case for: Supporters argue that this clause protects clinical judgment and provider autonomy, ensuring that healthcare professionals are not legally compelled to distribute medication against their professional assessment or if they lack the capacity to do so appropriately.
Case against: Critics might argue that this provision could create a loophole, potentially undermining the bill's intent to expand access by allowing providers to opt out of distribution, leading to inconsistent availability for at-risk individuals.
Estimated impact: The impact is likely localized, affecting specific instances where providers choose not to furnish the drug, rather than significantly altering the overall expanded access envisioned by the bill.